Goldman Sachs Asset Management to acquire Synthon International from BC Partners for $2.1bn.

Goldman Sachs Asset Management, a provider of investment management solutions, agreed to acquire Synthon International, an international pharmaceutical company, from BC Partners, a private equity firm, for $2.1bn. "We look forward to collaborating with management to drive value creation through product and pipeline development and operational excellence initiatives as well as execute on our joint vision to strengthen Synthon’s global impact. Synthon’s track record and expertise in complex drug development, intellectual property formation, and manufacturing position it well to capture the secular growth of generic medicines and increase access to affordable medicines for patients globally," Adam Dawson, Goldman Sachs Alternatives Managing Director and Global Co-Head of Healthcare Private Equity.